PPP4R2 and acute myeloid leukemia: We screened a cohort of primary AML patient samples (n = 89) including CN-AML patients with 3p CDR for mutations in PPP4R2. This cohort was selected based on gene expression profiling (GEP) data and included patients with high (n = 30), intermediate (n = 29), and low (n = 30) global PPP4R2 expression.